2,671 results match your criteria Expert opinion on biological therapy[Journal]


Recent advances in gelatin-based therapeutics.

Expert Opin Biol Ther 2019 Apr 22. Epub 2019 Apr 22.

a NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7 , Vitoria-Gasteiz 01006 , Spain .

Introduction: Biomaterials have provided a wide range of exciting opportunities in tissue engineering and regenerative medicine. Gelatin, a collagen-derived natural biopolymer, has been extensively used in regenerative medicine applications over the years, due to its cell-responsive properties and the capacity to deliver a wide range of biomolecules. Areas covered: The most relevant properties of gelatin as biomaterial are presented together with its main therapeutic applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1610383DOI Listing

An Evaluation of Mepolizumab for the Treatment of Severe Asthma.

Expert Opin Biol Ther 2019 Apr 22. Epub 2019 Apr 22.

c Department of Clinical and Experimental Medicine , University of Catania , Catania (CT) , Italy.

Introduction Asthma is considered one of the most common chronic conditions globally, characterized by variable airflow obstruction and symptoms. Severe asthma is diagnosed when asthma control requires high-intensity therapy or continues to remain uncontrolled despite treatment. Eosinophilic inflammation is known to be perpetuated by the activity of IL-5 in a proportion of severe asthma subjects, and targeting IL-5 may offer a therapeutic option. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1610382DOI Listing
April 2019
1 Read

Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar.

Expert Opin Biol Ther 2019 Apr 19:1-8. Epub 2019 Apr 19.

a Global Clinical Development, Biopharmaceuticals , Hexal AG (A Sandoz Company) , Holzkirchen , Germany.

Introduction: Antidrug antibody (ADA) development is known to occur with adalimumab treatment and impacts adalimumab exposure. Here, we compare the impact of immunogenicity on pharmacokinetics (PK) across two randomized PK studies of GP2017, an approved biosimilar adalimumab, in healthy subjects.

Methods: Healthy male subjects (N= 107 in study GP17-104; N= 90 in study GP17-103) received a single 40 mg subcutaneous injection of the same GP2017 drug product batch. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1603959DOI Listing

Current Knowledge of Ipilimumab and its use in Treating Non-small Cell Lung cancer.

Expert Opin Biol Ther 2019 Apr 19. Epub 2019 Apr 19.

d Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine , Baltimore , MD , USA.

Introduction: The systemic treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the identification of actionable mutations and the use of targeted agents. Unfortunately, many tumors will acquire resistance and >75% of NSCLC cases lack for an actionable gene aberration. In this setting, immunotherapy rises as effective therapeutic where immune checkpoint inhibitors have entered or are entering the market in many neoplasms, including NSCLC. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1610380DOI Listing
April 2019
2 Reads

Facing the future: challenges and opportunities in adoptive T cell therapy in cancer.

Expert Opin Biol Ther 2019 Apr 15. Epub 2019 Apr 15.

a Department of Oncology-Pathology , Karolinska Institutet , Stockholm , Sweden.

Introduction: In recent years, immunotherapy for the treatment of solid cancer has emerged as a promising therapeutic alternative. Adoptive cell therapy (ACT), especially T cell-based, have been found to cause tumor regression and even cure in a percentage of treated patients. Checkpoint inhibitors further underscore the potential of the T cell compartment in the treatment of cancer. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1608179DOI Listing
April 2019
3 Reads

Mesenchymal Stromal Cells for Ocular Surface Repair.

Expert Opin Biol Ther 2019 Apr 12. Epub 2019 Apr 12.

a Student. Institute of Genetic Medicine, Newcastle University, International Centre for Life , Newcastle upon Tyne , UK.

Introduction: Cornea is a transparent, robust tissue that comprises highly organized cells. Disruption of this specialized tissue, can lead to scarring and subsequent blindness, making corneal damage a considerable challenge worldwide. At present, the available medical treatments are unable to address the wide range of corneal diseases. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1607836DOI Listing
April 2019
4 Reads

Andexanet alfa for the reversal of factor Xa inhibitors.

Expert Opin Biol Ther 2019 May 11;19(5):387-397. Epub 2019 Apr 11.

a Namur Thrombosis and Haemostasis Center, Hematology Laboratory , Université catholique de Louvain, CHU UCL Namur , Yvoir , Belgium.

Introduction: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding. On 28 of February 2019, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a conditional marketing authorization for andexanet alfa in Europe. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1599355DOI Listing
May 2019
4 Reads

Universal influenza virus vaccines: what needs to happen next?

Expert Opin Biol Ther 2019 Apr 8:1-13. Epub 2019 Apr 8.

a Health Planning Unit , Liguria Health Authority (A.Li.Sa) , Genoa , Italy.

Introduction: Influenza occurs worldwide and causes significant disease burden in terms of morbidity, associated complications, hospitalizations, and deaths. Vaccination constitutes the primary approach for controlling influenza. Current influenza vaccines elicit a strain-specific response yet occasionally exhibit suboptimal effectiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1604671DOI Listing

IL-17 inhibition in axial spondyloarthritis: current and future perspectives.

Expert Opin Biol Ther 2019 Apr 6:1-11. Epub 2019 Apr 6.

b Department of Gastroenterology , Infectiology and Rheumatology, Campus Benjamin Franklin, Charité - Universitätsmedizin , Berlin , Germany.

Introduction: Interleukin (IL)-17 is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of ankylosing spondylitis (AS)/axial spondyloarthritis (axSpA) as well as of other spondyloarthritides. There is a number of substances targeting IL-17, which are at different stages of development in the axSpA indication. Areas covered: This review summarizes the current evidence on the role of IL-17 in the pathophysiology of axSpA and provided a comprehensive review of clinical and radiographic outcomes as well as of safety data from studies with IL-17A inhibitors secukinumab and ixekizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1605352DOI Listing
April 2019
3 Reads

Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.

Expert Opin Biol Ther 2019 Apr 1:1-14. Epub 2019 Apr 1.

c Department of Pharmaceutical Science, School of Pharmacy, Bouve College of Health Sciences , Northeastern University , Boston , MA , USA.

Introduction: Immuno-oncology is currently the most popular field of cancer research and development. The surge of interest in immuno-oncology stems from recent clinical approvals and successes in clinical trials with new immuno-therapeutics and parallels a global trending interest in immunology. Among the current immunotherapeutic modalities, immune checkpoint inhibitors (ICPIs) are some of the most prominent agents that strengthens the activity of our adaptive immune system, and has demonstrated success in treating different types of cancer. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1602605DOI Listing
April 2019
5 Reads

Poxvirus oncolytic virotherapy.

Expert Opin Biol Ther 2019 Mar 28:1-13. Epub 2019 Mar 28.

a Biodesign Center for Immunotherapy, Vaccines and Virotherapy , Arizona State University , Tempe , AZ , USA.

Introduction: Over the last decade, advances in biological therapies have resulted in remarkable clinical responses for the treatment of some previously incurable cancers. Oncolytic virotherapy is one of these promising novel strategies for cancer therapy. A successful oncolytic virus promotes tumor cell oncolysis and elicits a robust long-term anti-tumor immunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1600669DOI Listing
March 2019
3 Reads

Ramucirumab: the long and winding road toward being an option for mCRC treatment.

Expert Opin Biol Ther 2019 May 16;19(5):399-409. Epub 2019 Apr 16.

b Department of Oncology, Unit of Oncology 1 , Veneto Institute of Oncology, Scientific Institute for Research and Healthcare (IRCCS) , Padua , Italy.

Introduction: Colorectal cancer (CRC) is one of the main causes of cancer-related morbidity and mortality worldwide. Mortality is most often attributable to metastatic disease. Despite the progress achieved so far, life expectancy continues to be limited in most patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1600505DOI Listing

Current and emerging biologics for the treatment of hereditary angioedema.

Expert Opin Biol Ther 2019 Mar 26:1-10. Epub 2019 Mar 26.

b Department of Biomedical and Clinical Sciences Luigi Sacco , University of Milan , Milan , Italy.

Introduction: Hereditary angioedema due to C1-INH deficiency (C1-INH-HAE) is a rare disease with unpredictable, self-limiting and localized swelling episodes involving the cutaneous and subcutaneous tissues. In the last decade, the spectrum of the possibilities to control the disease has considerably changed with the development of biologic therapies making necessary a careful evaluation of the differences among current and emerging treatments to properly optimize the management of patients. Areas covered: This review serves to summarize the literature regarding the use of biologics for the treatment of C1-INH-HAE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1595581DOI Listing
March 2019
2 Reads

Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

Expert Opin Biol Ther 2019 May 25;19(5):443-455. Epub 2019 Mar 25.

a Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine , University of Helsinki , Helsinki , Finland.

Introduction: Oncolytic adenoviruses are among the most studied oncolytic viruses because of their tumor selectivity, safety, and transgene-delivery capability. With a growing number of different immunotherapies against cancer, the extraordinary immunogenicity of the adenovirus has emerged as a differentiating strength. Enabling T-cell related therapies with oncolytic adenoviruses appears a promising approach due to its inherent ability to elicit responses from the adaptive immune compartment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1595582DOI Listing

Endogenous lung stem cells for lung regeneration.

Expert Opin Biol Ther 2019 Mar 22:1-8. Epub 2019 Mar 22.

a School of Health and Biomedical Sciences , RMIT University , Melbourne , Australia.

Introduction: Lifelong maintenance of a healthy lung requires resident stem cells to proliferate according to tissue requirements. Once thought to be a quiescent tissue, evolving views of the complex differentiation landscape of lung stem and progenitor cells have broad implications for our understanding of how the lung is maintained, as well as the development of new therapies for promoting endogenous regeneration in lung disease. Areas covered: This review collates a large body of research relating to the hierarchical organization of epithelial stem cells in the adult lung and their role in tissue homeostasis and regeneration after injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1596256DOI Listing
March 2019
1 Read

Stem cell therapies for wound healing.

Expert Opin Biol Ther 2019 Mar 22:1-11. Epub 2019 Mar 22.

a Hagey Laboratory for Pediatric Regenerative Medicine; Division of Plastic and Reconstructive Surgery, Department of Surgery , Stanford University School of Medicine , Stanford , CA , USA.

Introduction: Aberrant wound healing is a significant healthcare problem, posing a substantial burden on patients, their families, and the healthcare system. Existing treatment options remain only moderately effective and often fail to promote the closure of non-healing wounds in susceptible populations, such as aging and diabetic patients. Stem cell therapy has emerged as a promising treatment modality, with the potential to restore tissue to its pre-injured state. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1596257DOI Listing

Defining the immunogram of breast cancer: a focus on clinical trials.

Expert Opin Biol Ther 2019 May 1;19(5):383-385. Epub 2019 Apr 1.

a Division of Early Drug Development for Innovative Therapy , IEO, European Institute of Oncology IRCCS , Milan , Italy.

In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall survival in metastatic triple-negative breast cancer patients. This benefit was significant only in patients harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is needed to achieve consistent responses. Besides PD-L1 expression, a variety of potential biomarkers are under investigation for predicting immunotherapy efficacy in breast cancer, such as tumor-infiltrating lymphocytes, gene signatures, tumor mutational burden, microsatellite instability, and gut microbiome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1598372DOI Listing

An overview of tolerogenic immunotherapies based on plant-made antigens.

Expert Opin Biol Ther 2019 Mar 20:1-13. Epub 2019 Mar 20.

a Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas , Universidad Autónoma de San Luis Potosí , San Luis Potosí , México.

Introduction: Over the last two decades, genetically engineered plants became attractive and mature platforms for producing vaccines and other relevant biopharmaceuticals. Autoimmune and inflammatory disorders demand the availability of accessible treatments, and one alternative therapy is based on therapeutic vaccines able to downregulate immune responses that favor pathology progression. Areas covered: The current status of plant-made tolerogenic vaccines is presented with emphasis on the candidates under evaluation in test animals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1597048DOI Listing
March 2019
1 Read

Expert opinion on the use of biological therapy in non-infectious uveitis.

Expert Opin Biol Ther 2019 May 16;19(5):477-490. Epub 2019 Apr 16.

r Inflammation-Immunopathology-Biotherapy Department (DHU i2B) , Sorbonne Universités, UPMC Univ Paris 06, UMR 7211 , Paris , France.

Introduction: Conventional immunosuppressive drugs, anti-TNF alpha treatments and biotherapies are increasingly being used in non-infectious uveitis. Areas covered: The present work was led by a multidisciplinary panel of experts, including internal medicine specialists, rheumatologists and ophthalmologists, and proposes an extensive review on the use of biological agents in non-infectious uveitis. Expert opinion: In case of dependency to steroids or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or biological therapies such as anti-TNF alpha treatments (adalimumab, infliximab) can be used to achieve and maintain disease quiescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1595578DOI Listing
May 2019
1 Read

Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors.

Expert Opin Biol Ther 2019 May 8;19(5):433-442. Epub 2019 Apr 8.

a Department of Medicine , University of Perugia , Perugia , Italy.

Introduction: Treatment with biological agents interfering with mechanisms of angiogenesis, such as vascular endothelial growth factor (VEGF) signaling pathway (VSP) inhibitors, was associated with an enhanced risk of acute and severe blood pressure (BP) increase and development of hypertensive emergencies. Areas covered: The present article will review the scientific literature reporting hypertensive emergencies as a complication of biological treatment with VSP inhibitors. Hypertensive emergency is a life-threatening condition characterized by very high BP values (>180/110 mmHg) associated with acute organ damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1594770DOI Listing
May 2019
2 Reads

FOLFOXIRI plus biologics in advanced colorectal cancer.

Expert Opin Biol Ther 2019 May 27;19(5):411-422. Epub 2019 Mar 27.

b Edificio Sur 7ª planta , Amgen S.A. Moll de Barcelona s/n , Barcelona , Spain.

Introduction: The combination of oxaliplatin, irinotecan, fluorouracil (5-FU), and leucovorin (FOLFOXIRI) results in improved outcomes compared with standard chemotherapy when used in frontline to treat patients with metastatic colorectal cancer (mCRC). FOLFOXIRI has been recently combined with biologic agents aiming further improvement in outcomes. Areas covered: This manuscript provides a comprehensive review of the results achieved by the FOLFOXIRI+biologic combination when used as first-line treatment in patients with mCRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1595580DOI Listing

Bioengineering and regeneration of gastrointestinal tissue: where are we now and what comes next?

Expert Opin Biol Ther 2019 Mar 16:1-11. Epub 2019 Mar 16.

a Wake Forest Institute for Regenerative Medicine , Wake Forest School of Medicine , Winston Salem , NC , USA.

Introduction: The field of tissue engineering and regenerative medicine has been applied to the gastrointestinal (GI) tract for a couple decades. Several achievements have been accomplished that provide promising tools for treating diseases of the GI tract. Areas covered: The work described in this review covers the traditional aspect of using cells and scaffolds to replace parts of the tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1595579DOI Listing
March 2019
3.743 Impact Factor

Immunotherapy for small cell lung cancer: mechanisms of resistance.

Expert Opin Biol Ther 2019 May 18;19(5):423-432. Epub 2019 Mar 18.

a Department of Surgery , Medical University of Vienna , Vienna , Austria.

Introduction: Small cell lung cancer (SCLC) is a highly malignant disease with a dismal prognosis that is currently being tested for theclinical activity of checkpoint inhibitors. SCLC is associated with smoking and exhibits a high mutational burden. However, low expression of PD-L1 and MHC antigens, as well low levels of immune cell infiltration and rapid tumor progress seems to limit the efficacy of anticancer immunity. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1592155DOI Listing
May 2019
24 Reads

Correction.

Authors:

Expert Opin Biol Ther 2019 Apr 7;19(4):381. Epub 2019 Mar 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1589718DOI Listing
April 2019
1 Read

Tocilizumab for the treatment of adult-onset Still's disease.

Expert Opin Biol Ther 2019 Apr;19(4):273-286

b Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases , Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander , Spain.

Introduction: Adult-onset Still´s disease (AOSD) is a systemic inflammatory condition that affects mainly young people. The clinical course consists of two distinctive patterns: one with a predominance of systemic symptoms and another manifested by progressive chronic polyarthritis. Glucocorticoids remain the mainstay in the treatment of AOSD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1590334DOI Listing
April 2019
11 Reads

Towards personalized treatment in atopic dermatitis.

Expert Opin Biol Ther 2019 May 26;19(5):469-476. Epub 2019 Feb 26.

a National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology , University Medical Center Utrecht , Utrecht , The Netherlands.

Introduction: For many years, oral immunosuppressive drugs such as cyclosporine A, azathioprine, mycophenolic acid, and methotrexate were the only treatment options, in addition to topical treatment, in patients with severe atopic dermatitis (AD). Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha, is the first antibody-based treatment commercially available for the treatment of AD. In the near future, more antibody-based treatments and small molecules will become available in the treatment of severe AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1583204DOI Listing
May 2019
9 Reads

A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.

Expert Opin Biol Ther 2019 Apr 27;19(4):343-360. Epub 2019 Feb 27.

a Academic Unit of Obstetrics and Gynecology , Ospedale Policlinico San Martino , Genoa , Italy.

Introduction: Endometriosis is a chronic benign estrogen-dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity. Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating disease-related pain, some women experience partial or no improvement of pain or its recurrence is frequent after discontinuation of the therapies. For these reasons, new drugs are under investigation for the treatment of endometriosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1581761DOI Listing
April 2019
1 Read

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.

Expert Opin Biol Ther 2019 May 27;19(5):457-467. Epub 2019 Feb 27.

a Cancer Biology and Precision Medicine , Institute for Health Science Research Germans Trias i Pujol (IGTP) , Badalona , Spain.

Introduction: Biological therapies, with immunotherapy leading the field, have arisen as one of the quickest expanding areas of research for cancer treatment in the last few years. The clear benefits for patients are undeniable, satisfying the long-awaited necessity of a target-specific therapy. However, its full potential remains still unexploited due to a lack of response in a majority of patients and pending reliable biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1582635DOI Listing
May 2019
9 Reads

Advances in stem cell therapy for male stress urinary incontinence.

Expert Opin Biol Ther 2019 Apr 15;19(4):293-300. Epub 2019 Feb 15.

a Department of Surgery, Division of Urology , San Paolo Hospital , Savona , Italy.

Introduction: Among the several options that have been proposed in recent years for the management of male stress urinary incontinence (SUI), stem cell therapy represents a new frontier in treatment. The aim of this paper is to update the current status of stem cell therapy in animal and human studies for the management of iatrogenic male SUI. Areas covered: A literature review was conducted based on MEDLINE/PubMed searches for English articles using a combination of the following keywords: stem cell therapy, urinary incontinence, prostatectomy, regenerative medicine, mesenchymal stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1578343DOI Listing
April 2019
1 Read

Advances in stem cell treatment for sciatic nerve injury.

Expert Opin Biol Ther 2019 Apr 11;19(4):301-311. Epub 2019 Feb 11.

a Neuroscience Research Center, Faculty of Medicine , Guilan University of Medical Sciences , Rasht , Iran.

Introduction: The sciatic nerve is one of the peripheral nerves that is most prone to injuries. After injury, the connection between the nervous system and the distal organs is disrupted, and delayed treatment results in distal organ atrophy and total disability. Regardless of great advances in the fields of neurosurgery, biological sciences, and regenerative medicine, total functional recovery is yet to be achieved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1576630DOI Listing

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.

Expert Opin Biol Ther 2019 Jan 30:1-9. Epub 2019 Jan 30.

a Global Clinical Development, Biopharmaceuticals , Hexal AG (A Sandoz company) , Holzkirchen , Germany.

Background: To compare the pharmacokinetics of Sandoz biosimilar adalimumab (GP2017) with reference adalimumab (Humira) in healthy volunteers (PK similarity study) and to compare the pharmacokinetics of GP2017 administered by autoinjector (AI) or prefilled syringe (PFS; delivery study).

Methods: Healthy male subjects were randomized to receive a single 40 mg subcutaneous injection of GP2017, US-licensed or EU-authorized reference adalimumab (US/EU-Humira; PK similarity study) or a single 40 mg subcutaneous injection of GP2017 via AI or PFS (delivery study). Pharmacokinetics, safety, and immunogenicity were assessed over 72 days post-injection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1571580DOI Listing
January 2019

Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD.

Expert Opin Biol Ther 2019 Apr 11;19(4):361-366. Epub 2019 Feb 11.

a Inflammatory Bowel Disease Center and Amsterdam Gastroenterology and Metabolism , Amsterdam UMC, University of Amsterdam , Amsterdam , The Netherlands.

Introduction: Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression in gut-associated lymphoid tissue is upregulated in patients with inflammatory bowel disease (IBD). Blocking adhesion molecules and thereby inhibiting migration of lymphocytes into sites of inflammation in the gut is an attractive new treatment target in drug development for IBD. Areas covered: This review discusses the preclinical and clinical experience on SHP647 (previously called PF-00547659 and PF-00547,659), a fully human IgG2K monoclonal antibody that binds to MAdCAM-1 to selectively reduce lymphocyte homing to the intestinal tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1576631DOI Listing
April 2019
2 Reads

Complement inhibition as a therapeutic strategy in retinal disorders.

Expert Opin Biol Ther 2019 Apr 11;19(4):335-342. Epub 2019 Feb 11.

d Retinal Consultants of Arizona, Phoenix, Arizona; USC Roski Eye Institute, Keck School of Medicine , University of Southern California , Los Angeles , CA , USA.

Introduction: Dry age-related macular degeneration (AMD) and Stargardt Macular Dystrophy (STGD1) result in vision loss due to progressive atrophy of the macula and lack of effective treatments. Numerous studies have implicated complement-associated inflammation as a contributor to both diseases. Areas covered: The complement factor D inhibitor, lampalizumab, failed to halt geographic atrophy (GA) progression in phase 3 studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1575358DOI Listing
April 2019
1 Read
3.743 Impact Factor

Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells.

Expert Opin Biol Ther 2019 Apr 7;19(4):313-333. Epub 2019 Feb 7.

a Division of Cardiology, Department of Medicine , University of Ottawa Heart Institute , Ottawa , Canada.

Introduction: Inherited arrhythmias are an uncommon, but malignant family of cardiac diseases that result from genetic abnormalities in the ion channels and/or structural proteins within cardiomyocytes. Given the inherent differences between species and the limited reproducibility of in vitro heterologous cell models, progress in understanding the mechanisms underlying these malignant diseases has always languished far behind the clinical science and need. The ability to study human induced pluripotent stem cells (iPSCs) derived cardiomyocytes promises to change this paradigm as patient cells have the potential to become testing platforms for disease phenotyping or therapeutic discovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1575359DOI Listing
April 2019
2 Reads

Current and emerging biologic and small molecule therapies for atopic dermatitis.

Expert Opin Biol Ther 2019 Apr 7;19(4):367-380. Epub 2019 Feb 7.

a Department of Dermatology, Laboratory of Inflammatory Skin Diseases , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease, yet until recently there were no safe systemic therapies approved for the long-term management of AD in adult patients. A deeper understanding of disease pathogenesis and identification of molecular and cellular changes has resulted in a rapidly evolving pipeline of therapeutics that holds promise for safer long-term control. Areas covered: In this review, we highlight the growing arsenal of biologic and small molecule antagonists that target pathways implicated in AD pathogenesis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1573422DOI Listing
April 2019
6 Reads

Development of new agents for peripheral T-cell lymphoma.

Expert Opin Biol Ther 2019 03 29;19(3):197-209. Epub 2019 Jan 29.

a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.

Introduction: Peripheral T-cell lymphoma (PTCL) is a relatively rare, heterogeneous group of mature T-cell neoplasms generally associated with poor prognosis, partly because of refractoriness against conventional cytotoxic chemotherapies. To improve the outcome of patients with PTCL, the clinical development of several novel agents is currently under investigation. Areas covered: Since the first approval of pralatrexate (dihydrofolate reductase inhibitor) by the US Food and Drug Administration, belinostat, romidepsin (histone deacetylase inhibitors), and brentuximab vedotin (anti-CD30 antibody-drug conjugate) have been approved in the US, and many other countries. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1572746DOI Listing
March 2019
21 Reads

Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.

Expert Opin Biol Ther 2019 03 25;19(3):225-232. Epub 2019 Jan 25.

a Thoracic Oncology Department , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.

Introduction: Immunotherapy, either as monotherapy or in combination with chemotherapy, has demonstrated superior efficacy to chemotherapy alone in the frontline setting. To date, there has been no randomized study comparing immunotherapy alone with chemo-immunotherapy. Areas Covered: This paper reviews the immunobiological rationale for combining chemotherapy with checkpoint inhibitors as well as the data from recent phase-3 studies to understand the risks and benefits associated with either therapeutic approach for diverse patient populations. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1571036DOI Listing
March 2019
10 Reads

An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders.

Expert Opin Biol Ther 2019 03 25;19(3):233-248. Epub 2019 Jan 25.

a Department of Anatomy and Embryology, Faculty of Medicine , University of Granada , Granada , Spain.

Introduction: Adipose-derived mesenchymal stem cells (ASCs) represent a new therapeutic strategy in biomedicine with many potential applications, especially in musculoskeletal disorders. Preclinical and clinical studies based on the administration of ASCs support their efficacy in bone regeneration, joint repair, tendon injury and skeletal muscle alterations. Many of these novel treatments may improve patients' quality of life and prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1563069DOI Listing
March 2019
3 Reads

CheckMate 141 trial: all that glitters is not gold.

Expert Opin Biol Ther 2019 03 21;19(3):169-171. Epub 2019 Jan 21.

e Department of Precision Medicine , University of Campania "L. Vanvitelli" , Naples and Biogem , Avellino Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1570498DOI Listing
March 2019
2 Reads

B cell depletion in the treatment of multiple sclerosis.

Expert Opin Biol Ther 2019 03 23;19(3):261-271. Epub 2019 Jan 23.

c Department of Neurology , Akershus University Hospital , Lørenskog , Norway.

Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has been a large step forward in the treatment of this devastating disease. Areas covered: In this manuscript, we review mechanisms of action, efficacy, safety, and tolerance of anti-CD20 therapies for MS, including rituximab, ocrelizumab, and ofatumumab. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1568407DOI Listing
March 2019
11 Reads

The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.

Expert Opin Biol Ther 2019 Jan 8. Epub 2019 Jan 8.

a IBD Unit, Presidio Columbus , Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore , Rome.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566455DOI Listing
January 2019
3 Reads

Etanercept biosimilar SB-4.

Expert Opin Biol Ther 2019 03 11;19(3):173-179. Epub 2019 Jan 11.

a Rheumatology Clinic, Department of Internal Medicine, Medical School , University of Ioannina , Ioannina , Greece.

Introduction: Biosimilars are highly similar molecules to other biological medicines that have already been authorized for use. Etanercept (ETN) was the first anti-tumor necrosis factor inhibitor (TNFi) approved by the Food and Drug Administration for the treatment of moderate to severe rheumatoid arthritis (RA) in November 1998 and in February 2000 by the European Medicines Agency. Twenty years later, the first ETN biosimilar has come of age. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1566456DOI Listing
March 2019
16 Reads
3.743 Impact Factor

Intra-arterial administration of cell-based biological agents for ischemic stroke therapy.

Expert Opin Biol Ther 2019 03 21;19(3):249-259. Epub 2019 Jan 21.

a 2nd Department of Radiology, Division of Interventional Radiology, School of Medicine , National and Kapodistrian University of Athens, Attikon University Hospital , Athens , Greece.

Introduction: Ischemic stroke is becoming a primary cause of disability and death worldwide. To date, therapeutic options remain limited focusing on mechanical thrombolysis or administration of thrombolytic agents. However, these therapies do not promote neuroprotection and neuro-restoration of the ischemic area of the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566454DOI Listing
March 2019
4 Reads

MDA-7/interleukin 24 (IL-24) in tumor gene therapy: application of tumor penetrating/homing peptides for improvement of the effects.

Expert Opin Biol Ther 2019 03 21;19(3):211-223. Epub 2019 Jan 21.

c Bacteriology and Virology Department, School of Medicine , Shiraz University of Medical Sciences , Shiraz , Iran.

Introduction: MDA-7/Interleukin-24 (IL-24), as a pleiotropic cytokine, exhibits a specific tumor suppression property that has attracted a great deal of attention. While its anti-tumor induction is mostly attributed to endogenous gene expression, attachment of secreted MDA-7/IL-24 to cognate receptors also triggers the death of cancerous cell via different pathways. Therefore, precise targeting of secreted MDA-7/IL-24 to tumor cells would render it more efficacy and specificity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566453DOI Listing
March 2019
3 Reads

Biosimilars of adalimumab: the upcoming challenge in IBD.

Expert Opin Biol Ther 2019 Jan 2. Epub 2019 Jan 2.

a IBD Center, Department of Gastroenterology , Humanitas Clinical and Research Institute , Rozzano, Milan , Italy.

Introduction Biosimilars represent great potential in cost saving and re-investment opportunities in healthcare and allow patients greater access to effective mAbs. Infliximab biosimilars are successfully used in all indications for whom the reference product (RP) was approved. Areas covered In late 2018, adalimumab biosimilars will also be available in patients with inflammatory bowel disease (IBD). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1564033DOI Listing
January 2019
7 Reads

Characteristics of biological therapy in pediatric patients with Crohn's disease.

Expert Opin Biol Ther 2019 03 11;19(3):181-196. Epub 2019 Jan 11.

d Pediatric Institute-Clinic , University of Debrecen , Debrecen , Hungary.

Introduction: At present, there is a significant amount of data related to biologics used in pediatric patients with Crohn's disease. This review characterizes the different biological drugs administered in this population. Areas covered: Biological therapy of CD, focusing on children, is summarized in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1564034DOI Listing
March 2019
3 Reads

Direct cellular reprogramming and inner ear regeneration.

Expert Opin Biol Ther 2018 Dec 25. Epub 2018 Dec 25.

a Department of Otolaryngology-Head and Neck Surgery , Stanford University School of Medicine , Stanford , CA , 94305 , USA .

Introduction: Sound is integral to communication and connects us to the world through speech and music. Cochlear hair cells are essential for converting sounds into neural impulses. However, these cells are highly susceptible to damage from an array of factors, resulting in degeneration and ultimately irreversible hearing loss in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1564035DOI Listing
December 2018
2 Reads

The rise of human stem cell-derived natural killer cells for cancer immunotherapy.

Expert Opin Biol Ther 2018 Dec 24:1-8. Epub 2018 Dec 24.

b Department of Medicine, Division of Regenerative Medicine , University of California San Diego , San Diego , CA , USA.

Introduction: Natural killer (NK) cell therapy has been proven to be safe and clinically effective for the treatment of multiple cancers, in particular blood cancers. Most of the clinical trials use primary NK cells from peripheral blood or umbilical cord blood, or NK-92 cells. Each cell source is confined by limitations, such as donor dependence, low persistence in vivo, and its difficulty to genetically modify. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1559293DOI Listing
December 2018
3 Reads

Are hair follicle stem cells promising candidates for wound healing?

Expert Opin Biol Ther 2018 Dec 21. Epub 2018 Dec 21.

a Wound Healing and Cell Biology Laboratory, Institute of Basic Medicine Science, College of Life Science , Chinese PLA General Hospital , 28 Fuxing Road, Beijing , 100853 , People's Republic of China.

Introduction:With the continued focus on in-depth investigations of hair follicle stem cells (HFSCs), the role of HFSCs in wound healing has attracted increasing attention from researchers. This review may afford meaningful implications for HFSC treatment of wounds. Areas covered: We present the properties of HFSCs, analyze the possibility of HFSCs in wound healing, and sum up the recent studies into wound repair with HFSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1559290DOI Listing
December 2018
5 Reads